Disialoganglioside GD2 as a therapeutic target for human diseases

Maya Suzuki, Nai Kong V. Cheung

研究成果: Contribution to journalReview article査読

86 被引用数 (Scopus)

抄録

Introduction: Ganglioside GD2 is found in vertebrates and invertebrates, overexpressed among pediatric and adult solid tumors, including neuroblastoma, glioma, retinoblastoma, Ewing's family of tumors, rhabdomyosarcoma, osteosarcoma, leiomyosarcoma, liposarcoma, fibrosarcoma, small cell lung cancer and melanoma. It is also found on stem cells, neurons, some nerve fibers and basal layer of the skin.Areas covered: GD2 provides a promising clinical target for radiolabeled antibodies, bispecific antibodies, chimeric antigen receptor (CAR)-modified T cells, drug conjugates, nanoparticles and vaccines. Here, we review its biochemistry, normal physiology, role in tumorigenesis, important characteristics as a target, as well as anti-GD2-targeted strategies.Expert opinion: Bridging the knowledge gaps in understanding the interactions of GD2 with signaling molecules within the glycosynapses, and the regulation of its cellular expression should improve therapeutic strategies targeting this ganglioside. In addition to anti-GD2 IgG mAbs, their drug conjugates, radiolabeled forms especially when genetically engineered to improve therapeutic index and novel bispecific forms or CARs to retarget T-cells are promising candidates for treating metastatic cancers.

本文言語英語
ページ(範囲)349-362
ページ数14
ジャーナルExpert Opinion on Therapeutic Targets
19
3
DOI
出版ステータス出版済み - 3 1 2015
外部発表はい

All Science Journal Classification (ASJC) codes

  • 分子医療
  • 薬理学
  • 創薬
  • 臨床生化学

フィンガープリント

「Disialoganglioside GD2 as a therapeutic target for human diseases」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル